TXMD TherapeuticsMD Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TXMD

Price (delayed)

$1.99

Market cap

$23.03M

P/E Ratio

99.5

Dividend/share

N/A

EPS

$0.02

Enterprise value

$19.44M

?
Relative Growth: Rel. Growth: 69
Relative Strength: Rel. Strength: 78
Relative Valuation: Rel. Valuation: 43
Relative Profitability: Rel. Profitability: 55

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women ...

Highlights
The company's EPS has surged by 140% QoQ and by 111% YoY
The net income has soared by 131% from the previous quarter and by 109% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.therapeuticsmd.com
Peers: ABBV RPRX PFE

Key stats

What are the main financial stats of TXMD

TXMD stock price

How has the TherapeuticsMD stock price performed over time
Intraday
1.02%
1 week
-5.69%
1 month
-1.49%
1 year
76.11%
YTD
22.09%
QTD
-1.49%

Financial performance

How have TherapeuticsMD's revenue and profit performed over time
Revenue
$3.35M
Gross profit
$3.35M
Operating income
-$3.83M
Net income
$179,000
Gross margin
100%
Net margin
5.3%
The net income has soared by 131% from the previous quarter and by 109% YoY
TXMD's net margin has surged by 128% since the previous quarter and by 105% year-on-year
The gross profit has soared by 82% YoY and by 11% from the previous quarter
TXMD's revenue has soared by 82% year-on-year and by 11% since the previous quarter

Price vs fundamentals

How does TXMD's price correlate with its fundamentals

Growth

What is TherapeuticsMD's growth rate over time

Valuation

What is TherapeuticsMD stock price valuation
P/E
99.5
P/B
0.85
P/S
6.87
EV/EBIT
93
EV/EBITDA
11.91
EV/Sales
5.8
The company's EPS has surged by 140% QoQ and by 111% YoY
The stock's price to book (P/B) is 42% more than its last 4 quarters average of 0.6
TXMD's revenue has soared by 82% year-on-year and by 11% since the previous quarter
TXMD's price to sales (P/S) is 33% lower than its 5-year quarterly average of 10.1 but 19% higher than its last 4 quarters average of 5.7

Efficiency

How efficient is TherapeuticsMD business performance
The ROIC has soared by 140% from the previous quarter and by 111% YoY
The company's return on sales has surged by 133% QoQ and by 105% YoY
TherapeuticsMD's ROE has soared by 133% from the previous quarter and by 109% YoY
TXMD's return on assets has surged by 133% since the previous quarter and by 109% year-on-year

Dividends

What is TXMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TXMD.

Financial health

How did TherapeuticsMD financials performed over time
TXMD's quick ratio is up by 29% year-on-year and by 3% since the previous quarter
TherapeuticsMD's current ratio has increased by 18% YoY and by 3% from the previous quarter
TXMD's debt is 82% smaller than its equity
TXMD's debt is down by 19% year-on-year and by 6% since the previous quarter
TXMD's debt to equity is down by 18% year-on-year and by 5% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.